Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00113841 · OUTCOME

Percent Change of NF-kB Protein Expression in Peripheral Blood Mononuclear Cells From Baseline Through 4 Weeks of Treatment

Curcumin (Diferuloylmethane Derivative) With or Without Bioperine in Patients With Multiple Myeloma · Source last updated 2011-11-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
Percent reduction
Interval / dispersion
Standard Deviation
Time frame
Baseline through 4 weeks of treatment

What was measured

Percent change of NF-kB =\[(expression at 4 weeks- expression at baseline)/expression at baseline\]\*100%. Bone marrow aspirate/biopsy for expression of NF-kB and related genes/proteins markers at baseline and after 4 weeks.

Analysis population: All participants in the two arms (Curcumin versus Curcumin plus Bioperine) who received at least 4 weeks of treatment were eligible for outcome evaluation.

Groups in this outcome

Curcumin

Curcumin starting dose 2 grams orally in two divided doses (a.m., p.m.)

Curcumin + Bioperine

Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Curcumin15
Curcumin + Bioperine15

Reported measurements

Source class 1
Values in Percent reduction · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
Curcumin2137Not reportedNot reportedNot reported
Curcumin + Bioperine3725Not reportedNot reportedNot reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Pct Value
    95
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.16
    statistical Method
    t-test, 2 sided
    tested Non Inferiority
    false
Complete source fields
analyses
  1. ci Pct Value
    95
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY_OR_OTHER
    p Value
    0.16
    statistical Method
    t-test, 2 sided
    tested Non Inferiority
    false
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        37
        value
        21
      2. group Id
        OG001
        spread
        25
        value
        37
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    2. group Id
      OG001
      value
      15
    units
    Participants
description
Percent change of NF-kB =\[(expression at 4 weeks- expression at baseline)/expression at baseline\]\*100%. Bone marrow aspirate/biopsy for expression of NF-kB and related genes/proteins markers at baseline and after 4 weeks.
dispersion Type
Standard Deviation
groups
  1. description
    Curcumin starting dose 2 grams orally in two divided doses (a.m., p.m.)
    id
    OG000
    title
    Curcumin
  2. description
    Curcumin starting dose 2 grams orally in 2 divided doses (a.m., p.m.) and Bioperine 5 mg orally twice daily
    id
    OG001
    title
    Curcumin + Bioperine
param Type
MEAN
population Description
All participants in the two arms (Curcumin versus Curcumin plus Bioperine) who received at least 4 weeks of treatment were eligible for outcome evaluation.
reporting Status
POSTED
time Frame
Baseline through 4 weeks of treatment
title
Percent Change of NF-kB Protein Expression in Peripheral Blood Mononuclear Cells From Baseline Through 4 Weeks of Treatment
type
PRIMARY
unit Of Measure
Percent reduction

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice